Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of ifosfamide when added to olaratumab and doxorubicin in participants with soft tissue sarcoma (STS) that is advanced or has spread to another part(s) of the body.
The results of this study are not yet available.
Your participation could last up to 16 weeks, depending on how you and your tumor respond
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have been diagnosed with advanced soft tissue sarcoma
Participant must have adequate blood and organ function
Participant must have stopped other anti-cancer treatment and must have recovered from side effects of that treatment, except for hair loss
Female and male participant who is able to have children must agree to use birth control during the study and for 12 weeks after the last dose of study drug. Female participant must not be pregnant or breastfeeding
Participant must not be enrolled in another clinical trial
Participant must not have received anticancer treatment that targets the entire body (like chemotherapy) or radiotherapy of the chest or pelvis
Participant's cancer must not be actively spreading to the central nervous system or brain
Participant must not have active infections, including HIV or hepatitis
Participant must not have a mental illness or social situation that would make it hard to meet the study requirements
Participant must not be planning/need major surgery during the study